Mineralys Therapeutics
Trade Mineralys Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MLYS
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease.
MLYS Key Statistics
Stock Snapshot
With a market cap of 2B, Mineralys Therapeutics(MLYS) trades at $24.32. The stock has a price-to-earnings ratio of -10.52.
On 2026-03-18, Mineralys Therapeutics(MLYS) stock moved within a range of $23.60 to $24.53. With shares now at $24.32, the stock is trading +3.1% above its intraday low and -0.9% below the session's peak.
Trading volume for Mineralys Therapeutics(MLYS) stock has reached 1.56M, versus its average volume of 1.41M.
Over the past 52 weeks, Mineralys Therapeutics(MLYS) stock has traded between a high of $47.65 and a low of $10.44.
Over the past 52 weeks, Mineralys Therapeutics(MLYS) stock has traded between a high of $47.65 and a low of $10.44.
Analyst ratings
88%
of 8 ratingsPeople also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.